CClinicalTrials.gg
RecruitingNCT06343558GALVANISEUpdated Aug 3, 2025

Gait and Balance Impairment in Rare and Very Rare Neurological Diseases

An observational study in Multiple Sclerosis, Parkinson Disease and Peripheral Neuropathy, sponsored by Istituto Auxologico Italiano. Recruiting at 2 sites in Italy. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Istituto Auxologico Italiano · Observational

From the registry’s dates

  • Started May 2023; still recruiting 3 years 4 months later.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
200
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Rare and very rare neurological diseases primarily or exclusively affect the nervous system with a prevalence of \< 5 out of 10'000 and 100'000 people, respectively. Besides these, there are undiagnosed neurological diseases: neurological conditions without a diagnosis after completing a full diagnostic examination.

Rare, very rare, and undiagnosed neurological diseases are complicated and progressive and often cause variegated motor signs, impairments, and syndromes.

Balance and gait are frequently affected in these conditions, already at the clinical examination. These balance and gait impairments limit activities and cause an increased risk of falling. Falls can eventually result in injuries, even severe.

There are only a few studies about these diseases, likely because of their rarity. Hence, the clinical presentation and the course of rare and very rare diseases are poorly known or even unknown. Essential information for these conditions' diagnosis, prognosis, treatment and rehabilitation is missing.

MaNeNeND is an observational study underway at the Fondazione IRCCS Istituto Neurologico "Carlo Besta" (Milano) aimed at detailing the clinical and biological features of very rare and undiagnosed neurological diseases.

Research questions:

  1. Do patients with rare (Ra), very rare (V) and undiagnosed (U) neurological diseases suffer a balance and gait impairment?
  2. Is there a correlation between the clinical and instrumental severity of the balance and gait impairment in RaVU neurological diseases?
  3. Are instrumental measures more sensitive in detecting balance and gait impairments in patients affected by a RaVU neurological disease than the clinical measures?
  4. Do the balance and gait impairments in RaVU neurological diseases worsen in time?

The current project aims at diagnosing, quantifying and detailing the balance and gait impairment in rare, very rare and undiagnosed neurological diseases.

To this aim, questionnaires, clinical scales and instrumental tests will be administered to these patients to collect a wide range of balance and gait measures.

These measures will also integrate those collected with MaNeNeND to provide a more detailed description of patients with rare, very rare and diagnosed neurological diseases.

Participants will complete two questionnaires: the Dizziness Handicap Inventory - short form (DHI-sf, an ordinal score of self-perceived balance) and the Modified Fatigue Impact Scale (MFIS, an ordinal score of self-perceived fatigue).

Moreover, a clinician will administer the Mini Balance Evaluation Systems Test (Mini-BESTest, an ordinal score of balance), the 10 m walking test (for measuring the gait speed and other gait parameters) and the Timed Up and Go test (an instrumental measure of mobility and balance). Walking and the Timed Up and Go tests will be recorded with a trunk-worn inertial measurement unit.

Finally, participants will be asked to complete an instrumental upright stance and gait assessment, the first consisting of standing on posturographic plates and the second of walking on a treadmill equipped with force sensors. When walking on the treadmill, an optoelectronic system will also record the position in time of limbs and trunk.

The quantification of the severity of the balance and gait impairment of the patients suffering a rare, very rare or undiagnosed neurological disease will highlight these persons' therapeutic and rehabilitative needs.

Comparing the balance and gait impairment of rare, very rare and undiagnosed diseases with those of multiple sclerosis, Parkinson's disease and peripheral neuropathy will highlight if the formers' balance and gait impairment has unique characteristics that could help ease the diagnosis of these uncommon conditions.

The longitudinal measurements on rare, very rare and undiagnosed diseases will be paramount to identifying prognostic factors.

In addition, the data collected in the current study will be crucial for future studies, for example, for estimating the sample size in clinical trials.

02

Conditions studied

  • Multiple Sclerosis
  • Parkinson Disease
  • Peripheral Neuropathy
  • Rare Diseases
  • Healthy
  • Healthy Aging

Keywords

  • Rare neurological diseases
  • Very rare neurological diseases
  • Undiagnosed neurological diseases
  • Upright stance
  • Balance
  • Risk of falling
  • Gait analysis
  • Posturography
03

In context

Multiple Sclerosis

3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.

This study's planned enrollment of 200 is above the median of 100 across 1,016 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Istituto Auxologico Italiano is the lead sponsor of 196 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with a balance and gait impairment secondary to multiple sclerosis, Parkinson's disease, peripheral neuropathy of the lower limbs, a rare, ultrarare or undiagnosed neurological disease.

A group of age-matched controls will also be recruited.

Inclusion criteria

  • Multiple sclerosis, Parkinson's disease, peripheral neuropathy of the lower limbs or rare or ultrarare neurological disease (e.g. la Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome - CANVAS, ORPHAcode: 504476; Wilson's disease, ORPHAcode: 905)
  • undiagnosed neurological disease, i.e. a neurological disease that remains unknown after a full diagnostic assessment;
  • age > 18 years;
  • ability to stand upright with no assistance and no assistive device for > 30 seconds;
  • ability to walk without assistance and with no assistive device for > 50 m;
  • ability to give their informed consent.

Exclusion criteria

Exclusion criteria

  • pregnancy or breastfeeding
  • any other medical conditions affecting by itself balance and gait (e.g. lower limb amputation, hemiparesis due to a stroke)
  • major orthopaedic surgery (e.g. hip or knee replacement).
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Healthy controls

    Other: Questionnaires, clinical scales and instrumental tests

  • Parkinson's disease patients

    Other: Questionnaires, clinical scales and instrumental tests

  • Multiple sclerosis patients

    Other: Questionnaires, clinical scales and instrumental tests

  • Peripheral neuropathies of the lower limbs

    Other: Questionnaires, clinical scales and instrumental tests

  • Rare and ultrarare neurological diseases

    Other: Questionnaires, clinical scales and instrumental tests

Interventions

  • OtherQuestionnaires, clinical scales and instrumental tests

    Questionnaires, clinical scales and instrumental tests to collect a wide range of balance and gait measures.

06

What researchers measure

Primary outcomes

  1. Balance (Mini-BESTest)

    Mini Balance Evaluation Systems Test (Mini-BESTest, an ordinal score of balance)

    Time frame: At enrollment

  2. Balance (Timed Up and Go test)

    Timed Up and Go test instrumented with inertial sensors

    Time frame: At enrollment

  3. Gait speed

    10 m walking test

    Time frame: At enrollment

  4. Gait analysis - kinematic - stride length

    Stride length, right step length and left step length

    Time frame: At enrollment

  5. Gait analysis - kinematic - duration

    Stride duration, right and left step duration

    Time frame: At enrollment

  6. Gait analysis - kinematic - width of the base of support

    Width of the base of support

    Time frame: At enrollment

  7. Gait analysis - kinematic - dorsal ankle angle

    Dorsal ankle angle

    Time frame: At enrollment

  8. Gait analysis - dynamic - reaction force

    Anterior-posterior, mediolateral and vertical reaction force

    Time frame: At enrollment

  9. Gait analysis - dynamic - ankle power

    Right and left ankle power

    Time frame: At enrollment

  10. Gait analysis - dynamic - energy

    Potential and kinetic energy of the body centre of mass

    Time frame: At enrollment

  11. Posturography - static - centre of pressure position

    Centre of pressure position while standing

    Time frame: At enrollment

  12. Posturography - static - centre of mass position

    Centre of mass position while standing

    Time frame: At enrollment

  13. Posturography - dynamic - centre of pressure position

    Centre of pressure position after base of support perturbations

    Time frame: At enrollment

  14. Posturography - dynamic - centre of mass position

    Centre of mass position after base of support perturbations

    Time frame: At enrollment

07

Study locations

1 of 2 sites recruiting
  • IRCCS Istituto Auxologico Italiano
    Milan, Milan, Italy
    Recruiting
  • IRCCS Istituto Neurologico Carlo Besta
    Milan, Italy
    Active, not recruiting
08

References and documents

Publications

  • Reinhard C, Bachoud-Levi AC, Baumer T, Bertini E, Brunelle A, Buizer AI, Federico A, Gasser T, Groeschel S, Hermanns S, Klockgether T, Krageloh-Mann I, Landwehrmeyer GB, Leber I, Macaya A, Mariotti C, Meissner WG, Molnar MJ, Nonnekes J, Ortigoza Escobar JD, Perez Duenas B, Renna Linton L, Schols L, Schuele R, Tijssen MAJ, Vandenberghe R, Volkmer A, Wolf NI, Graessner H. The European Reference Network for Rare Neurological Diseases. Front Neurol. 2021 Jan 14;11:616569. doi: 10.3389/fneur.2020.616569. eCollection 2020. PubMed 33519696 ↗
  • The Lancet Neurology. Rare neurological diseases: a united approach is needed. Lancet Neurol. 2011 Feb;10(2):109. doi: 10.1016/S1474-4422(11)70001-1. No abstract available. PubMed 21256450 ↗
  • Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ. Will my patient fall? JAMA. 2007 Jan 3;297(1):77-86. doi: 10.1001/jama.297.1.77. PubMed 17200478 ↗
  • Vieira ER, Palmer RC, Chaves PH. Prevention of falls in older people living in the community. BMJ. 2016 Apr 28;353:i1419. doi: 10.1136/bmj.i1419. No abstract available. PubMed 27125497 ↗
  • Caronni A, Sterpi I, Antoniotti P, Aristidou E, Nicolaci F, Picardi M, Pintavalle G, Redaelli V, Achille G, Sciume L, Corbo M. Criterion validity of the instrumented Timed Up and Go test: A partial least square regression study. Gait Posture. 2018 Mar;61:287-293. doi: 10.1016/j.gaitpost.2018.01.015. Epub 2018 Jan 31. PubMed 29413799 ↗
  • Picardi M, Redaelli V, Antoniotti P, Pintavalle G, Aristidou E, Sterpi I, Meloni M, Corbo M, Caronni A. Turning and sit-to-walk measures from the instrumented Timed Up and Go test return valid and responsive measures of dynamic balance in Parkinson's disease. Clin Biomech (Bristol). 2020 Dec;80:105177. doi: 10.1016/j.clinbiomech.2020.105177. Epub 2020 Sep 18. PubMed 32979787 ↗
  • Caronni A, Gervasoni E, Ferrarin M, Anastasi D, Brichetto G, Confalonieri P, Di Giovanni R, Prosperini L, Tacchino A, Solaro C, Rovaris M, Cattaneo D, Carpinella I. Local Dynamic Stability of Gait in People With Early Multiple Sclerosis and No-to-Mild Neurological Impairment. IEEE Trans Neural Syst Rehabil Eng. 2020 Jun;28(6):1389-1396. doi: 10.1109/TNSRE.2020.2991636. Epub 2020 Apr 30. PubMed 32356754 ↗
  • Scarano S, Sansone VA, Ferrari Aggradi CR, Carraro E, Tesio L, Amadei M, Rota V, Zanolini A, Caronni A. Balance impairment in myotonic dystrophy type 1: Dynamic posturography suggests the coexistence of a proprioceptive and vestibular deficit. Front Hum Neurosci. 2022 Jul 28;16:925299. doi: 10.3389/fnhum.2022.925299. eCollection 2022. PubMed 35967003 ↗
  • Scarano S, Rota V, Tesio L, Perucca L, Robecchi Majnardi A, Caronni A. Balance Impairment in Fahr's Disease: Mixed Signs of Parkinsonism and Cerebellar Disorder. A Case Study. Front Hum Neurosci. 2022 Mar 9;16:832170. doi: 10.3389/fnhum.2022.832170. eCollection 2022. PubMed 35355583 ↗

Individual participant data

Plan to share: No — The database will be made available upon request on Zenodo.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06343558
Lead sponsor
Istituto Auxologico Italiano
Collaborators
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
May 30, 2023
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Aug 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion